Literature DB >> 21601221

Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis.

Jing-Song Chen1, Qian Wang, Xi-Lin Chen, Xiao-Hui Huang, Li-Jian Liang, Jian Lei, Jiong-Qiang Huang, Dong-Ming Li, Zhi-Xiang Cheng.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) has a high predilection for portal vein invasion. Furthermore, the treatment of HCC with portal vein tumor thrombosis (PVTT) is controversial. The objective of this study was to investigate clinicopathologic characteristics and surgical outcomes of HCC patients with PVTT.
METHODS: The clinicopathologic data and surgical outcomes of 88 patients HCC with PVTT and 211 patients without PVTT who underwent surgery were retrospectively reviewed. The risk factors and the prognosis of HCC patients with PVTT were determined.
RESULTS: Cirrhosis, serum alkaline phosphatase (ALP) > 100 IU/L, tumor size > 8 cm, incomplete tumor capsule, and adjacent organ invasion were risk factors for PVTT in HCC on multivariate analysis. Furthermore, HCC patients with PVTT received more major hepatectomies, had more intraoperative blood loss and greater blood transfusion requirements, and higher incidence of postoperative mortality compared with HCC patients without PVTT. The median overall survival of HCC patients with PVTT after surgery was 9 mo, with the 1-, 2-, and 3-y overall survival rates of 31.1%, 18.3%, and 15.2 %, respectively. AFP level, adjacent organ invasion, and PVTT location predicted overall survival of HCC patients with PVTT.
CONCLUSIONS: High serum ALP level, cirrhosis, large tumor, incomplete tumor capsule and adjacent organ invasion are predictors of PVTT in HCC. Surgery is a valid therapy for selected HCC patients with PVTT.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601221     DOI: 10.1016/j.jss.2011.03.072

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  18 in total

1.  Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum.

Authors:  Yufu Tang; Hongming Yu; Long Zhang; Kang Wang; Weixing Guo; Jie Shi; Shupeng Liu; Mengchao Wu; Hongyang Wang; Shuqun Cheng
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

2.  Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis.

Authors:  Li Zhou; Jing-An Rui; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu
Journal:  Pathol Oncol Res       Date:  2014-06-08       Impact factor: 3.201

Review 3.  Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.

Authors:  Su Jong Yu; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2015-06-18

4.  Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma.

Authors:  Bao-Hong Yuan; Wei-Ping Yuan; Ru-Hong Li; Bang-De Xiang; Wen Feng Gong; Le-Qun Li; Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-09-17

5.  Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma.

Authors:  Brian I Carr; Vito Guerra; Rossella Donghia; Volkan Ince; Sami Akbulut; Veysel Ersan; Sertac Usta; Burak Isik; Emine Samdanci; Sezai Yilmaz
Journal:  J Gastrointest Surg       Date:  2021-09-10       Impact factor: 3.452

6.  Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis.

Authors:  Li Shaohua; Wang Qiaoxuan; Sun Peng; Li Qing; Yang Zhongyuan; Shi Ming; Wei Wei; Guo Rongping
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

7.  14-3-3ζ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1α.

Authors:  Yufu Tang; Shupeng Liu; Nan Li; Weixing Guo; Jie Shi; Hongming Yu; Long Zhang; Kang Wang; Shangrong Liu; Shuqun Cheng
Journal:  Oncotarget       Date:  2016-03-29

Review 8.  Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion.

Authors:  Jian-Hong Zhong; A Chapin Rodríguez; Yang Ke; Yan-Yan Wang; Lin Wang; Le-Qun Li
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

9.  Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Biao Yang; Xin You; Min Lan Yuan; Tian Qiang Qin; Lin Jia Duan; Jiao He; Ze Jun Fei; Xuan Zhou; Rui Yu Zan; Zheng Yin Liao
Journal:  Hepat Mon       Date:  2016-07-23       Impact factor: 0.660

10.  Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus.

Authors:  Biao Yang; Chun-Lin Li; Wen-Hao Guo; Tian-Qiang Qin; He Jiao; Ze-Jun Fei; Xuan Zhou; Lin-Jia Duan; Zheng-Yin Liao
Journal:  BMC Cancer       Date:  2018-01-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.